Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Antibody-targeted immunoliposomes for cancer treatment.

Gao J, Chen H, Song H, Su X, Niu F, Li W, Li B, Dai J, Wang H, Guo Y.

Mini Rev Med Chem. 2013 Dec;13(14):2026-35. Review.

PMID:
24251805
2.

Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor.

Manjappa AS, Chaudhari KR, Venkataraju MP, Dantuluri P, Nanda B, Sidda C, Sawant KK, Murthy RS.

J Control Release. 2011 Feb 28;150(1):2-22. doi: 10.1016/j.jconrel.2010.11.002. Epub 2010 Nov 21. Review.

PMID:
21095210
3.

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC.

J Control Release. 2001 Jul 6;74(1-3):95-113.

PMID:
11489487
4.

Immunoliposomes.

Paszko E, Senge MO.

Curr Med Chem. 2012;19(31):5239-77. Review.

PMID:
22934774
5.

[In vitro and in vivo targeting therapy of immunoliposomes against human gastric cancer].

Xu L, Zhang XY, Zhang SY.

Zhonghua Yi Xue Za Zhi. 1994 Feb;74(2):83-6, 126. Chinese.

PMID:
8069726
6.

Antibody-targeted liposomes in cancer therapy and imaging.

Sofou S, Sgouros G.

Expert Opin Drug Deliv. 2008 Feb;5(2):189-204. doi: 10.1517/17425247.5.2.189. Review.

PMID:
18248318
7.

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Park JW, Benz CC, Martin FJ.

Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. Review.

PMID:
15717745
8.

Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes.

Koning GA, Kamps JA, Scherphof GL.

Cancer Detect Prev. 2002;26(4):299-307.

PMID:
12430634
9.

Immunoliposomes for cancer therapy.

Kontermann RE.

Curr Opin Mol Ther. 2006 Feb;8(1):39-45. Review.

PMID:
16506524
10.

Lymphoid tissue targeting of anti-HIV drugs using liposomes.

Désormeaux A, Bergeron MG.

Methods Enzymol. 2005;391:330-51.

PMID:
15721390
11.
12.

Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs.

Crosasso P, Brusa P, Dosio F, Arpicco S, Pacchioni D, Schuber F, Cattel L.

J Pharm Sci. 1997 Jul;86(7):832-9.

PMID:
9232525
13.

Adventures in targeting.

Allen TM, Sapra P, Moase E, Moreira J, Iden D.

J Liposome Res. 2002 Feb-May;12(1-2):5-12.

PMID:
12604033
14.

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW.

Cancer Res. 2006 Jul 1;66(13):6732-40.

15.

Immunotargeting of liposomes containing lipophilic antitumor prodrugs.

Mori A, Kennel SJ, Huang L.

Pharm Res. 1993 Apr;10(4):507-14.

PMID:
8483832
16.

Ligand-targeted liposomes for cancer treatment.

Sapra P, Tyagi P, Allen TM.

Curr Drug Deliv. 2005 Oct;2(4):369-81. Review.

PMID:
16305440
17.
18.

[Study on preparation and biodistribution of PEG-immunoliposomes with active carboxylic terminals].

Zhang YF, Xie SS, Hou XP, Gao X, Zhang S, Chen ZS.

Yao Xue Xue Bao. 2000 Nov;35(11):854-9. Chinese.

PMID:
11218866
19.

Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro.

Moradpour D, Compagnon B, Wilson BE, Nicolau C, Wands JR.

Hepatology. 1995 Nov;22(5):1527-37.

PMID:
7590672
20.

Ligand-targeted liposomal anticancer drugs.

Sapra P, Allen TM.

Prog Lipid Res. 2003 Sep;42(5):439-62. Review.

PMID:
12814645

Supplemental Content

Support Center